Dr. Benjamin D. Smith

Internal Medicine
1521 Gull Rd, 
Kalamazoo, MI 
Accepting New Patients
1521 Gull Rd, 
Kalamazoo, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Smith is a primary care provider, practicing in Internal Medicine in Kalamazoo, Michigan. Dr. Smith is rated as an Experienced provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Breast Cancer, Postmenopausal Osteoporosis, Osteoarthritis, Osteotomy, and Nephrectomy. Dr. Smith is currently accepting new patients.

His clinical research consists of co-authoring 272 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in MI
Hospital Affiliations
Borgess Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ASCENSION MEDICAL GROUP PROMED
1521 Gull Rd, Kalamazoo, MI 49048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2/Phase 3
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma In Situ and Early Invasive Breast Cancer
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma In Situ and Early Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 2
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Asciminib Add-On, Imatinib, Nilotinib
Study Phase: Phase 2
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: ABL001, Bosutinib
Study Phase: Phase 3
A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drugs: Fosciclopirox, Cytarabine
Study Phase: Phase 1/Phase 2
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Biological, Drug
Study Drugs: Cytarabine, Lintuzumab, Furosemide, Spironolactone
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

272 Total Publications

ASO Visual Abstract: Comparing Survival Differences Between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer.
ASO Visual Abstract: Comparing Survival Differences Between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer.
Journal: Annals of surgical oncology
Published: August 27, 2025
Similar Doctors
Advanced in Magnesium Deficiency
Dr. Kenneth A. Lombardi
Internal Medicine
Advanced in Magnesium Deficiency
Dr. Kenneth A. Lombardi
Internal Medicine
391 S Shore Dr, Suite 215, 
Battle Creek, MI 
 (19.6 miles away)
269-964-6262
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kenneth Lombardi is a primary care provider, practicing in Internal Medicine in Battle Creek, Michigan. Dr. Lombardi is rated as an Advanced provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Gitelman Syndrome, Iron Deficiency Anemia, Magnesium Deficiency, and Gastrointestinal Bleeding. Dr. Lombardi is currently accepting new patients.

Experienced in Magnesium Deficiency
Dr. Roderick S. Kim
Internal Medicine
Experienced in Magnesium Deficiency
Dr. Roderick S. Kim
Internal Medicine

Center For Physical Rehabilitation Inc

5060 Cascade Rd, Suite A, 
Grand Rapids, MI 
 (44.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Roderick Kim is a primary care provider, practicing in Internal Medicine in Grand Rapids, Michigan. Dr. Kim is rated as an Advanced provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Pulmonary Embolism, Primary Hyperoxaluria, Immunodeficiency with Hyper IgM Type 1, and Chorea-Acanthocytosis. Dr. Kim is currently accepting new patients.

Experienced in Magnesium Deficiency
Dr. Younho O. Chung
Internal Medicine
Experienced in Magnesium Deficiency
Dr. Younho O. Chung
Internal Medicine

Bronson Methodist Hospital

601 John St, 
Kalamazoo, MI 
 (1.7 miles away)
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Younho Chung is a primary care provider, practicing in Internal Medicine in Kalamazoo, Michigan. Dr. Chung is rated as a Distinguished provider by MediFind in the treatment of Magnesium Deficiency. His top areas of expertise are Spastic Paraplegia-Epilepsy-Intellectual Disability Syndrome, Spastic Paraplegia Type 5A, Spastic Paraplegia Type 2, Endoscopy, and Hip Replacement. Dr. Chung is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Smith's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 98 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile